Skip to content
thestock.space

On 6 Nov 2026, Granules India was priced at ₹799.65, or 28.0× trailing earnings, against an industry P/E of 28.7×, and the shares are 13% below their 52-week high. Sales and net profit grew 5.9% and 4.8% a year over 3 years, with ROCE of 15% and ROE of 14%. Debt is 0.17× equity, and its dividend yield is 0.2%. It is a small-cap company with a market cap of ₹21,813 Cr, ranked 21st of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 40% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year
Open
₹790.25
Day high
₹803.00
Day low
₹761.50
Prev. close
₹794.45
Volume
32.8 L

Health check

3 good · 2 fair · 1 to check
  • ReturnsAhead

    +39.9% over a year, better than 5 of 7 peers.

  • Price tagIn line

    P/E 28.0 vs industry 28.7.

  • GrowthSlow

    Sales +5.9%, profit +4.8% a year over 3 years.

  • ProfitabilityAverage

    ROCE 15.2% vs peer median 17.9%.

  • Balance sheetSolid

    Debt 0.17× equity, interest covered 12.0×, Piotroski 6 of 9.

  • Red flagsNone found

    No warning signs in the headline numbers.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹21,813 Cr, #21 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Sep 2026: sales ₹5,893 Cr · profit ₹714 Cr
Market cap
₹21,813 Cr
Small cap
P/E
28.0
Industry 28.7
Price to book
3.07
Peers 4.99
Dividend yield
0.22%
ROE
13.5%
Peers 14.7%
ROCE
15.2%
Peers 17.9%
Debt to equity
0.17
Debt ₹1,101 Cr
EPS (TTM)
₹28.57
Face value ₹1
OPM (TTM)
22.9%
Net margin 12.1%
Sales growth
+18.8%
Latest quarter vs a year ago
Profit growth
+39.2%
Latest quarter vs a year ago
Price to sales
3.70
EV/EBITDA 15.0

Strengths and risks

Strengths

  • Quarterly profit up 39.2% on a year ago.
  • Quarterly sales up 18.8% on a year ago.
  • Positive operating cash flow in each of the last 4 years.

No obvious red flags in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About Granules India

Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), finished dosages (FDs), and peptides CDMO in India and internationally. It offers paracetamol, metformin, guaifenesin, ibuprofen, and methocarbamol, as well as prescription and over-the-counter products. The company also develops and manufactures tablets, capsules, press fits, oral solutions, suspensions, and powder for…

Headquarters
Hyderabad
Employees
4,306
Sector
Healthcare
ISIN
INE101D01020
Website
granulesindia.com

Price range

52 weeks

₹529.85₹923.65

Today

₹761.50₹803.00
Avg volume (3M)
9.6 L
1-year return
plus 39.9%
From 52-week high
minus 13.4%

Analyst consensus

8 analysts
Strong buyMean target ₹907.25 plus 13.5%

Target range, with today’s price

Low ₹588.00High ₹1,045.00

Consensus from Yahoo Finance. Not a recommendation.

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.87%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.30%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.81%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.59%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.93%minus 6.6%
GRANULESGranules India799.65plus 0.65%21,81328.03.0715.2%13.5%22.9%5.9%4.8%0.22%plus 39.9%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.59%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrSep 25Dec 25Mar 26Jun 26Sep 26
1,2951,3781,4571,4651,538
1,0161,0701,1051,1261,201
278308352339338
21.5%22.4%24.2%23.1%21.9%
−1.1−3.68.82.310.7
29.228.732.721.121
7273.581.779.683.9
––15.9––
176202262240243
25.7%25.7%23.2%25.1%25.3%
131150202180182
5.386.198.237.127.03

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+5.9%
Profit CAGR 3Y
+4.8%
EPS CAGR 3Y
+5.2%
ROE
13.5%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
4,4964,4904,4565,339
–minus 0.1%minus 0.8%+19.8%
3,5743,6233,5014,142
9228689551,197
20.5%19.3%21.4%22.4%
−13.7−31.5−29.8−22.6
35.471.860.771.4
184207226296
−1.4−9.821.6−21.7
687547660785
24.8%25.9%24.0%24.2%
517405502595
–minus 21.5%+23.7%+18.6%
21.0016.7220.6824.46

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
24.224.224.324.8
2,8113,2013,6915,060
1,1361,3151,4551,512
9339801,0821,123
4,9055,5216,2537,720
1,9912,2602,8043,626
360404587575
21.221.5220.8
292381469933
2,2412,4552,3712,584
4,9055,5216,2537,720

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
739439867793
−191−360−691−773
−4407.7−92.5379
10786.982.8399
−411−381−572−558
32858.8295235
−18.6−36.3−36.4−36.4

Shareholding pattern

Source: NSE filings
37.4%
promoters
  • Promoters37.39%
  • Public62.61%
  • As of 30 Sep 2026
QuarterSplitPromotersPublicPromoter change
30 Sep 202637.39%62.61%0.00
16 Sep 202637.39%62.61%minus 0.63
30 Jun 202638.02%61.98%0.00
31 Mar 202638.02%61.98%0.00
23 Feb 202638.02%61.98%–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you